home / stock / vcka / vcka quote
Last: | $9.01 |
---|---|
Change Percent: | 9.7% |
Open: | $9.03 |
Close: | $9.01 |
High: | $10.52 |
Low: | $8.5 |
Volume: | 115,491 |
Last Trade Date Time: | 12/31/1969 07:00:00 pm |
Quotes are delayed by 15 to 20 minutes.
Last | Open | Close | High | Low | Volume | Date |
---|---|---|---|---|---|---|
$9.01 | $9.03 | $9.01 | $10.52 | $8.5 | 115,491 | 11-10-2022 |
$10 | $10.35 | $10 | $10.6 | $10 | 13,061 | 11-09-2022 |
$10.5 | $9.52 | $10.5 | $11.17 | $9.33 | 33,890 | 11-08-2022 |
$9.165 | $8.03 | $9.165 | $9.64 | $8.03 | 11,440 | 11-07-2022 |
$8.77 | $9.75 | $8.77 | $9.75 | $8.0697 | 12,197 | 11-04-2022 |
$10.428 | $10.44 | $10.428 | $10.44 | $10.42 | 57,127 | 11-03-2022 |
$10.422 | $10.42 | $10.422 | $10.44 | $10.42 | 23,256 | 11-02-2022 |
$10.43 | $10.44 | $10.43 | $10.44 | $10.4 | 75,741 | 11-01-2022 |
$10.4201 | $10.42 | $10.4201 | $10.425 | $10.42 | 2,915 | 10-31-2022 |
$10.42 | $10.42 | $10.42 | $10.42 | $10.42 | 1,885 | 10-28-2022 |
$10.42 | $10.4279 | $10.42 | $10.43 | $10.42 | 26,765 | 10-27-2022 |
$10.45 | $10.44 | $10.45 | $10.575 | $10.425 | 66,568 | 10-26-2022 |
$10.405 | $10.405 | $10.405 | $10.405 | $10.405 | 310 | 10-25-2022 |
$10.4001 | $10.4001 | $10.4001 | $10.4001 | $10.4001 | 1,102 | 10-24-2022 |
$10.4 | $10.41 | $10.4 | $10.41 | $10.4 | 66,566 | 10-21-2022 |
$10.42 | $10.39 | $10.42 | $10.42 | $10.39 | 12,692 | 10-20-2022 |
$10.39 | $10.38 | $10.39 | $10.4 | $10.38 | 435,086 | 10-19-2022 |
$10.39 | $0 | $10.39 | $0 | $0 | 127 | 10-18-2022 |
$10.39 | $10.4 | $10.39 | $10.4 | $10.39 | 612 | 10-17-2022 |
$10.39 | $10.39 | $10.39 | $10.39 | $10.39 | 201 | 10-14-2022 |
News, Short Squeeze, Breakout and More Instantly...
Vickers Vantage Corp. I Company Name:
VCKA Stock Symbol:
NASDAQ Market:
SEC declared Effectiveness of Vickers’s registration statement on Form S-4 Extraordinary General Meeting of Vickers Vantage Corp. I shareholders to approve the proposed Business Combination is scheduled to be held on November 9, 2022, at 10:00 a.m., Eastern Time Post-closin...
SP-103 receives Fast Track Designation, which makes it eligible for some or all of the following: More frequent meetings or written communication with the FDA to discuss the SP-103 development plan and ensure collection of appropriate data needed to support drug approval. ...
PALO ALTO, Calif., Aug. 17, 2022 (GLOBE NEWSWIRE) -- Scilex Holding Company (“Scilex”), a commercial biopharmaceutical company focused on developing and commercializing non-opioid therapies for patients with acute and chronic pain, today announced the signing of a Product Dist...